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Iatrogenic hypoparathyroidism is the most common complication of cervical endocrine surgery. Current man-
agement is limited and palliative. As the molecular steps in parathyroid development have been defi ned, they 
may be replicable in vitro, with a goal of cellular replacement therapy. Human embryonic stem cell (hESC) lines 
were investigated as a model for parathyroid regeneration in vitro. BG01 was selected as a model based on 
expression of genes of interest in embryoid bodies (EBs). Established strategies for mouse embryonic stem cell 
differentiation into defi nitive endoderm were modifi ed and extended to maximize the expression of defi nitive 
markers of parathyroid development. The optimal approach included the use of Activin A at 100 ng/mL with 
BG01 cells grown on murine embryonic fi broblasts for 5 days under conditions of increasing serum concentra-
tion. After 5 days, the cells were allowed to mature further in tissue culture without murine fi broblasts but with 
continuous Activin A. Our strategy produced differentiated cell cultures that expressed intermediate markers of 
endoderm and parathyroid development (CXCR4, EYA1, Six1, and Pax1), as well as markers of committed para-
thyroid precursors or developed parathyroid glands (glial cell missing-2 [Gcm2], CCL21, calcium sensing recep-
tor [CaSR], and parathyroid hormone [PTH]). We further characterized the cells by testing conditioned medium 
from various time points in our differentiation scheme for the presence of PTH. We found that by keeping the 
cells in culture 2 weeks after the withdrawal of Activin A, the cells were able to produce PTH. Further in vivo 
work will be needed to demonstrate proper functionality of the cells developed in this way.
Introduction
In humans, the parathyroid glands develop in the third and fourth pharyngeal pouches in contiguity with the 
developing thymus (third pharyngeal pouch) and parafolli-
cular cells of the thyroid (fourth pharyngeal pouch) [1]. In the 
last 10 years, a great deal has been learned about the molecu-
lar events in the development of the parathyroid glands and 
the thymus gland, mainly using mouse models.
In murine parathyroid development, positioning of pre-
cursor cells occurs at about day 10 in the third pouch endo-
derm [2]. Modern molecular tools have allowed dissection 
of the parathyroid organogenesis to separate thymus devel-
opment from parathyroid gland development (Fig. 1). Much 
of this work has been done in the process of studying the 
development of the thymus [3], demonstrating the parallel 
development of the parathyroid glands [2,4,5]. Thus, parathy-
roid development can be followed using well-characterized 
markers. Parathyroid precursor development is associated 
with expression of four specifi c transcription factors in the 
pharyngeal endoderm: Hoxa3, Pax1, Eya1, and Pax9. At this 
phase, the same transcription factors are also expressed 
in the cells that subsequently become thymus. The second 
phase of organogenesis, initiation, which includes the overt 
development of the conjoined thymus and parathyroid rudi-
ment, occurs at about day 11. There is no known difference 
in transcription factor expression between these two even-
tual organs at this stage of development, although one end of 
the rudiment subsequently becomes parathyroid while the 
other becomes thymus. This thymus and parathyroid pri-
mordium includes expression of Six1 and Pbx1. Engineered 
murine mutants that lack either of these transcription fac-
tors do not develop normal parathyroid glands [6,7].
The outgrowth and patterning phase of parathyroid 
development results in regional differences in the grow-
ing rudiment. This includes the development of separate 
transcription factor pathways between the two areas which 
occurs at about day 12. It appears that sonic hedgehog has an 
effect on the patterning. Sonic hedgehog is a secreted glyco-
protein expressed during development that binds to specifi c 
cell surface receptors and activates them. Sonic hedgehog, 
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variety of agents to try to recreate an endoderm phenotype 
and, particularly, a defi nitive endoderm that ultimately forms 
an adult organ rather than a part of the extra-embryonic tis-
sues of development [9–14]. The defi nitive endoderm is ini-
tially formed during gastrulation, at which time progenitor 
cells migrate through the primitive streak and emerge either 
as defi nitive endoderm or as mesoderm. Attempts to recapit-
ulate this endoderm differentiation process have included 
the use of factors that activate pathways used by nodal and 
transforming growth factor beta (TGF-β) [10].
Investigators have used mouse embryonic stem cells cul-
tured with and without serum and with Activin A (a TGF-
β-like molecule) in order to promote the formation of cells 
with endoderm potential [14]. These investigators have been 
able to generate defi nitive endoderm and mesoderm using 
Activin-A stimulation. Similar studies in human embryonic 
stem cell (hESC) lines support the concept that undiffer-
entiated cells can be promoted to differentiate through an 
intermediate meso-endoderm phase and to express genes 
consistent with defi nitive (not visceral) endoderm [10]. The 
next steps in the promotion of defi nitive endoderm cells to 
specifi c pharyngeal endoderm phenotype have not been 
demonstrated in any published literature.
Our goal is to defi ne conditions that can induce an undif-
ferentiated cell population to develop into parathyroid cells, 
to use for cellular replacement therapy. Parathyroid glands 
are optimal for cellular replacement therapy because: (1) 
each parathyroid cell contains the complete function of the 
organ, and the total number of cells needed is low; (2) no 
Bmp-4, and noggin act in a complex and complementary 
fashion to affect the outgrowth and patterning of the para-
thyroid precursor separate from the thymic precursor cells 
[4,8]. By murine embryonic day 13.5, the parathyroid cell 
mass and thymus cell mass are separate. They express dif-
ferent patterns of transcription factors. The thymic cells 
express Foxn1, which is not expressed in the parathyroid cell 
mass. Similarly, the parathyroid cells are the only cells in 
the embryo that express Gcm2 (glial cell missing-2 homolog, 
also known as GcmB), which makes this an excellent, spe-
cifi c marker for parathyroid differentiation [2]. The fi nal dif-
ferentiation phase of parathyroid development is specifi ed 
by the expression of the transcription factor Gcm2, as well 
as the mature parathyroid functional components calcium 
sensing receptor (CaSR) and parathyroid hormone (PTH). 
Gcm2 expression continues into adulthood only in the cells 
that produce parathyroid hormone and have simultaneous 
expression of the calcium sensing receptor controlling PTH 
production. Although the expression of these genes is both 
spatially and temporally correlated with parathyroid differ-
entiation (Fig. 1), only Gcm2 has been assigned a functional 
role in parathyroid development [5] and is a specifi c marker 
for parathyroid glands, even in the adult. The expression of 
the rest of the genes serves as markers of the third pharyn-
geal pouch differentiation.
In spite of this advanced understanding of the in vivo 
process of organogenesis, there is little known to date about 
methods for re-creating this process using less differenti-
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FIG. 1. (A) Parathyroid development. (a) Positioning of 
the eventual parathyroid cells in third pouch endoderm. 
At mouse embryonic Day 9.5, pharyngeal pouches have 
formed, and the cells that will become parathyroid cells are 
positioned in the third pouch (p3). In humans, parathyroid 
cells form from both the third and fourth pouches; however, 
there is no parathyroid development from the fourth pouch 
in mice. (b) Initiation of thymus and parathyroid cells. A 
distinct identity as a separate group of cells occurs at about 
embryonic Day 11 in the mouse. These are the only mouse 
cells that have this pattern of transcription factor expres-
sion (Hoxa3 and Eya1 expression also occurs in adjacent 
neural crest cells). (c) Growth and patterning. Expansion 
and regionalization of the thymus/parathyroid primordial 
cells occurs from Days 11.5 to 12.5 in the mouse embryo. The 
ventral portion of the cluster expresses Bmp4 and forms the 
thymus domain, while the dorsal portion expresses Noggin 
and becomes the parathyroid domain. Individual cells 
commit to either a GCM2-expressing parathyroid fate or a 
Foxn1-expressing thymus fate. (d) Separation of parathy-
roid rudiment from thymus. From Days 12 to 13.5, the para-
thyroid rudiment expands and separates from the thymus 
rudiment. Parathyroid-committed cells continue to be the 
only cells that express GCM2; other molecular changes are 
unknown, except that Noggin expression stops after separa-
tion. (Figure modifi ed with permission from Blackburn and 
Manley [2].) (B) Timeline of gene expression for parathyroid 
development.
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of differentiation. Cells were harvested at days 1, 2, 3, and 
5 for RNA isolation. For a schematic of the protocols used, 
see Figure 2.
Extended endoderm differentiation. BG01 cells were cul-
tured on MEFs in RPMI with Activin A per the D’Amour 
protocol for 5 days, followed by dispersion using TrypLE 
Select and re-plating on tissue culture plates containing 
Activin A and MEFs (MEF/ActA/TC) or gelatin, MEFs, and 
Activin A (MEF/ActA/Gel) with 5% FBS for 7 days, before 
harvesting. Control cultures included cells maintained on 
MEFs with continued Activin A exposure for 12 days (MEF/
ActA/12d). Some cultures were then fed in differentiation 
medium with 5% FBS without Activin A for 1 or 2 weeks post 
day 12 of Activin A exposure. At 1- or 2-week post exposure, 
RNA was isolated for RT-PCR analysis. For a schematic rep-
resentation of the best differentiation conditions (Bingham 
protocol), see Figure 3.
PCR
Total RNA was isolated using TRIzol reagent (Invitrogen, 
Carlsbad, CA) and cDNA synthesis was performed with 
ReactionReady First Strand cDNA synthesis kit (SuperArray, 
Frederick, MD) per the manufacturers’ instructions. PCR 
were performed using PCR primer sets spanning exon 
architectural arrangement of parathyroid cells is needed 
to support or enhance the function of the organ; and (3) 
transplantation of autologous parathyroid cells has been 
proven to reconstitute normal parathyroid function. We 
have used hESC lines as a model system to test culture 
conditions that promote this. These initial studies demon-
strate that we can induce the expression of markers of both 
parathyroid development and of mature parathyroid glands 
(CaSR, PTH, Gcm2, and CCL21). However, to be clinically 
applicable, this process must be replicated in an endogenous 
adult stem cell population to create cells for replacement of 
parathyroid function. The process defi ned here to differenti-
ate embryonic stem cells to a parathyroid-like phenotype is 
one step along that pathway.
Materials and Methods
Cell culture
Undifferentiated hESC lines were cultured under stan-
dard conditions. The lines were maintained on a feeder 
layer of irradiated mouse embryo fi broblasts (MEFs) at 
4 × 105 cells/60 mm 2 dish. The MEFs were supplied by the 
Michigan Center for Human Embryonic Stem Cell Research 
Core. The culture medium was hESC medium (DMEM/F12 
[Invitrogen, Carlsbad, CA], 20% Knockout Serum replacer 
[KOSR] [Invitrogen], nonessential amino acids [Invitrogen], 
2 mM l-glutamine [Invitrogen], 0.1 mM β-mercaptoethanol 
[Sigma, St. Louis, MO], and 4 ng/mL basic fi broblast growth 
factor [bFGF, Invitrogen]). Cultures were fed daily, and man-
ually passaged every 3–4 days using pulled glass pipettes. 
For some experiments, cells were passaged using enzymatic 
methods (TrypLE Select, Invitrogen). For experiments using 
growth on gelatin-covered plates, 0.1% gelatin was used to 
coat the plates (Sigma).
Differentiation protocols
Embryoid body formation. The presidentially approved 
hES cells BG01 were allowed to differentiate in the Michigan 
Center for Human Embryonic Stem Cell Research Core into 
embryoid bodies (EBs) by maintaining the cultures in hESC 
medium without MEFs or bFGF in nontissue culture plates. 
RNA was isolated at days 1, 3, 5, 7, 9, 12, and 14. For longer-
term evaluation of the embryoid body differentiation, cells 
were maintained without MEFs in culture for up to 5 weeks, 
and harvested at 1-week interval from weeks 2–5 for RT-PCR 
analysis.
Differentiation in high-dose Activin A. BG01 cell dif-
ferentiation into EBs was also performed at University of 
Michigan hESC core. Briefl y, BG01 cells were transferred 
to uncoated Petri dishes after mechanically removing them 
from the MEFs plate, and grown in DMEM-based medium 
without bFGF, in the presence or absence of Activin A (R&D 
Systems, Foster City, CA) 10 μg/mL and 20% KOSR. BG01 
EBs were grown in 20% KOSR and RNA was isolated at days 
1, 3, 5, 7, and 9 for RT-PCR analysis.
Defi nitive endoderm differentiation. BG01 cells were 
cultured on MEFs in RPMI supplemented with 100 ng/
mL Activin A, glutamax and varying concentrations of 
fetal bovine serum (FBS) per the protocol described by 
D’Amour [10]. FBS concentrations were 0% for the initial 24 
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FIG. 2. Experimental design. Timeline schematic of the 
differentiation protocols used to obtain endoderm. Different 
culture conditions were used for the cells starting at Day 5, 
but the resulting cells all expressed the same markers, so the 

























FIG. 3. Final differentiation protocol. Schematic represen-
tation of the protocol that ultimately resulted in cells that 
had parathyroid markers and expressed parathyroid hor-
mone (PTH) (Bingham protocol).
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Coulter, Inc., Fullerton, CA). Biologically replicated samples 
were each tested in duplicate.
Results
Embryoid body differentiation
BG01 hES cells were cultured without MEFs in stan-
dard hESC medium and formed EBs. EBs expressed endo-
derm markers Eya1 and Six1 without specifi c stimulation 
(Fig. 4A). There was no evidence of signifi cant expression 
of later endoderm or parathyroid markers, including Gcm2. 
However, EBs from cultured for 14–35 days expressed Pax1, 
HoxA3, Eya1, and Six1 (Fig. 4B). Based on these results, BG01 
cells did not appear to have a block or defect in the potential 
to develop into endoderm.
Since Activin A was previously used to differentiate 
hESC cells into endoderm, we incubated our BG01 EBs with 
various concentrations of Activin A to identify differentia-
tion effects mediated by Activin A. BG01 EBs in low levels of 
KOSR (1%) were sustained poorly. Expression of early pha-
ryngeal endoderm development markers suggests that the 
cells do not express markers of parathyroid development 
under these conditions.
Defi nitive endoderm differentiation
To further differentiate BG01 cells toward parathyroid-
like cells, we cultured undifferentiated BG01 cells for 5 days 
on MEFs in low-dose Activin A and increasing doses of FBS 
as per the protocol of D’Amour [10]. As the cells remained 
in culture, they developed changes in cellular structure 
and began expressing markers of endoderm development. 
Microscopically, cells changed from the typical hES appear-
ance to grow as monolayers of cuboidal cells without cyto-
plasmic projections (Fig. 5A, panels a–d). As previously 
described, the cells develop expression of FoxA2 and Sox17 
in response to the Activin A and serum stimuli (Fig. 5B; 
Table 2). The cells do not express more downstream markers 
of parathyroid gland development.
splicing sites (Superarray), GAPD internal standard primers, 
and PCR mix (Superarray). The catalog and accession num-
bers for the primer pairs are listed in Table 1. The RT-PCR 
products were separated on 2% agarose gels, stained with 
ethidium bromide, and visualized under UV. Gel images 
were documented with the BioRad ChemiDoc EQ system. 
Human parathyroid adenoma cDNA was used as the posi-
tive control for PCR. PCR protocol was one cycle at 95°C for 
15 min, then 30 cycles of 15 s at 95°C, 30 s at 55°C, and 30 s at 
72°C with a fi nal extension of 7 min at 72°C.
Immunofl uorescence
Cells were treated as stated earlier, removed from culture 
using TrypLE Select, and spun onto slides using a Cytospin 
4 (ThermoShandon [Thermo Scientifi c, Madison, WI]). Cells 
were fi xed in 2% paraformaldehyde at room temperature for 
15 min and blocked in goat serum at room temperature for 30 
min. Cells to be stained with CXCR4 or Sox17 were permea-
bilized with 0.1% Triton X-100 for 10 min at room tempera-
ture. Anti-CXCR4 (Cat# sc-53534; Santa Cruz Biotechnology, 
Inc., Santa Cruz, CA), anti-CaSR (Cat# sc-47741; Santa Cruz 
Biotech), and anti-Sox17 (Cat# sc-2009; Santa Cruz Biotech) 
were incubated with the cells overnight at 4°C. Cells were 
then exposed to appropriate secondary antibodies (goat anti-
rabbit IgG-FITC or goat anti-mouse IgG-FITC (Cat# sc-2012; 
sc-2010, Santa Cruz Biotech) for 30 min at room temperature. 
Cells were covered in glass using Prolong Gold antifade 
with Dapi (Molecular Probes, Eugene, OR) and stored in the 
dark at 4°C until analysis. Markers were visualized using a 
Leitz Laborlux S fl uorescent microscope (W. Nusbaum, Inc., 
Chicago, IL).
PTH ELISA
At each time point along the differentiation scheme 
(Fig. 2), conditioned medium was collected and stored at 
–80°C until use. Conditioned medium was thawed on ice, 
spun at 1000 rpm for 5 min. Supernatant was used in a 
commercial PTH ELISA kit (Cat# DSL-10–8000; Beckman 
Table 1. Primer Pairs Used for RT-PCR
Gene Full name
Super Array® 
catalog number Accession no.
FoxA2 Forkhead box A2 PPH00976A NM_021784
Sox17 SRY (sex determining 
region Y)-box 17
PPH02451A NM_0022454
CXCR4 Chemokine (c-x-c motif) receptor 4 PPH00621 NM_003467
Eya1 Eyes absent homolog 1 PPH10542A NM_000503
Six1 SIX homeobox 1 PPH09458A NM_005982
Hox3A Homeobox 3A PPH14990 NM_030661
Pax1 Paired box 1 PPH06915A NM_006192
Noggin Noggin PPH01926A NM_005450
Bmp-4 Bone morphogenic protein 4 PPH00546A NM_130851
Gcm2 Glial cells missing homolog 2 PPH02433A NM_004752
CaSR Calcium sensing receptor PPH02127 NM_000388
CCL21 Chemokine (C-C motif) ligand 21 PPH00541B NM_002989
PTH Parathyroid hormone PPH09061A NM_00315
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All BG01 cells that were treated with the 5-day D’Amour 
protocol expressed CXCR4 whether they were exposed to 
Activin A while on MEFs or, subsequent to EB differentia-
tion, in tissue culture dishes (Fig. 6; Table 3). The cells contin-
ued to grow as a monolayer of cuboidal cells (Fig. 5A; panels 
e–h). In addition, the timing of Activin A exposure and dif-
ferentiation status of the cells when exposed to Activin A 
did not have any effect on the development of FoxA2, Sox17, 
Eya1, Bmp4, or noggin expression. Therefore, cells allowed 
to differentiate for 5 days in Activin A expressed more mark-
ers of endoderm than EBs.
Parathyroid-like cell differentiation
BG01 cells that were cultured per the D’Amour protocol 
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FIG. 4. Expression of endoderm markers in human embry-
onic stem (hES) cell-derived embryoid bodies (EBs). (A) 
Expression of Hoxa3, Pax1, Eya1, Six1, and Gcm2 in spon-
taneously differentiated EBs from BG01 hES cell lines for up 
to 14 days. BG01 shows some expression of Six1 in particular, 
indicating that there is no block in the pathways to endoderm 
development in this line. BG01 was thus selected for further 
experiments. (B) Longer-term culture of BG01-derived EBs, 
up to 5 weeks, showed no evidence of further spontaneous 
development to endoderm or expression of parathyroid 
markers (Gcm2). PC is the positive control mRNA isolated 
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FIG. 5. BG01 cell differentiation with low-dose Activin A 
per the D’Amour protocol [10]. (A) Phase contrast images of 
cells under various culture conditions. Panels a and b: Con-
trol cells (no Activin A). Panels c and d: Cells cultured for 5 
days in Activin A. Panels e–h: Cells cultured for 12 days in 
Activin A. (B) RT-PCR expression of markers at Days 1–5 in 
Activin A culture. With exposure of BG01 cells to Activin A 
100 ng/mL and increasing FBS concentration over a 5-day 
period, the cells developed expression of markers associ-
ated with defi nitive endoderm. These include FoxA2 and 
Sox17, each of which increase over baseline. In addition, 
there is some induction of markers that appear in para-
thyroid development, including Eya1, BMP4, and noggin. 
There does not appear to be signifi cant induction of defi n-
itive markers of parathyroid development, such as the cal-
cium sensing receptor (CaSR), CCL21, Gcm2, or parathyroid 
hormone (PTH).
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did not appear to be a substantial difference in whether the 
extended differentiation was allowed to occur on tissue cul-
ture plates or gelatin. This procedure is hereafter referred to 
as the Bingham protocol.
Further differentiated BG01 cells (12d cells) had some 
markers of parathyroid cells, namely GCM2, CaSR, CXCR4, 
and PTH by RT-PCR. To determine if the 12 day cells also 
days (12 day cells) on tissue culture plates or gelatin-exhib-
ited marker expression characteristic of defi nitive endo-
derm, thymus/parathyroid primordium (Hoxa3, Pax1, Six1), 
and parathyroid precursor cells (Gcm2, CCL21, CaSR, PTH), 
compared to cells maintained on MEFs with only Activin 
A exposure or to cells that were allowed to differentiate to 
EBs prior to Activin A exposure (Fig. 6A; Table 3). There 
Table 2. Summary of Low-Dose Activin A Stimulation of BG01 
(D’Amour Protocol)
 24 h 48 h 72 h 5 days






 FoxA2 + ++ ++ ++
 Sox17 +++ +++ +++
 CXCR4
Thymus/parathyroid primordium markers
 Eya1 + + + ++ +




 Bmp4 + + + ++ ++
Committed parathyroid precursor cells or parathyroid gland
 Gcm2 + + +
 CaSR + + + +++++
 CCL21 +
 PTH +    + +++++





Protocol) MEF/ActA/Gel MEF/ActA/TC EB/ActA/FBS2 EB/ActA/FBS5
Endoderm markers
 FoxA2
 Sox17 + + +
 CXCR4 ++++ ++++ ++++ ++++ ++++
Thymus/parathyroid primordium markers
 Eya1 +++ +++ +++ +++ +++
 Six1 + ++ +++ + +
 Hoxa3 + +
 Pax1 + + ++ + +
 Noggin ++++ ++++ ++++ ++++ ++++
 Bmp4 ++ ++ ++ ++ ++
Committed parathyroid precursor cells or parathyroid gland
 Gcm2 ++ ++ + +
 CaSR ++ +++ +
 CCL21 + +
 PTH  ++ ++ + +
Abbreviations: MEF, mouse embryo fi broblast; ActA, Activin A; 12d, 12 days of Bingham protocol; 
Gel, gelatin-coated tissue culture plates; TC, uncoated tissue culture plates; EB, embryoid bodies; FBS2, 
2% fetal bovine serum; FBS5, 5% fetal bovine serum.
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FIG. 6. Extended differentiation of BG01 cells after Bingham protocol. (A) Expression of markers under various culture 
conditions. MEF/ActA/TC group was cultured on MEFs in RPMI with Activin A per the D’Amour protocol for 5 days, fol-
lowed by dispersion using TrypLE Select and re-plating on tissue culture plates with 5% FBS for 7 days; the MEF/ActA/Gel 
group was the same, but was plated on gelatin for the last 7 days. The MEF/ActA/12d treatment was maintained on MEFs 
with Activin A exposure throughout. The EB/ActA/FBS2 group was allowed to differentiate into EBs on tissue culture 
plates for 5 days before dispersion with TrypLE Select and growth on gelatin while being treated with Activin A 100 ng/
mL and FBS 2% for 7 days; the EB/ActA/FBS5 was the same but maintained in FBS 5%. Initial exposure to Activin A while 
cultured on MEFs, followed by extended differentiation on either gelatin or a tissue culture plate, appears to enhance the 
appearance of downstream parathyroid development markers. (B) Immunofl uorescence for Sox17 (top row), an endoderm 
marker; CXCR4 (middle row), an epithelial cell marker; and CaSR (bottom row), calcium sensing receptor, in cells that were 
cultured under various conditions. Abbreviations: MEF, mouse embryo fi broblasts; Con, control, no Activin A exposure; Act 
A d5, 5 days in Activin A under D’Amour differentiation conditions; Act A d12, 12 days in Activin A under Bingham proto-
col conditions. The bar is 40 μm. Note that most of the cells stain positive for all three markers, indicating that the cells are 
similar to those that become functional parathyroid. (Continued)
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2 weeks. At 1 week, the cells had a very fl at, vaculated 
appearance (Fig. 6D; panel a) and little to no PTH expres-
sion by ELISA (Fig. 6C). At 2 weeks, the cells had a more 
uniform cuboidal appearance (Fig. 6D; panel b) and PTH 
expression (Fig. 6C).
Taken together, the data presented here indicate that this 
approach can use hESC cells, differentiate them through 
the endoderm stage, and make cells that express markers 
of parathyroid tissue. To our knowledge, this is the fi rst 
description of in vitro differentiation into parathyroid-like 
tissue.
Discussion
Loss of parathyroid gland function (hypoparathyroid-
ism) is the most frequent permanent complication of thyroid 
and parathyroid surgery, and is also common after abla-
tive laryngeal operations. The four parathyroid glands are 
small and delicate structures that share their blood supply 
with the thyroid gland. Although autografting damaged 
parathyroids is widely recognized as the best approach 
to preventing hypoparathyroidism, the rate of perma-
nent hypoparathyroidism after thyroid surgery is 1–15% 
[15]. Hypoparathyroidism results in chronic hypocalcemia 
and low-turnover bone disease that is poorly managed by 
currently available replacement methods. There are cur-
rently many thousands of people living with this iatrogenic 
condition.
For several reasons, diseased parathyroids are optimal 
for cellular replacement therapy. The normal parathyroid 
cell detects serum calcium concentration through calcium-
sensing receptors expressed on the cell surface [16]. The sig-
nal transduction apparatus of the cell modulates the release 
of intracellularly produced PTH into the circulation based 
on serum calcium levels and not on any trophic hormonal 
signals or permissive microenvironment. The parathyroid 
cell needs only access to the circulation to provide the com-
plete function of the organ. The total weight of parathyroid 
tissue in normal people is 150–200 mg; re-implantation of 
far smaller amounts (<50 mg) of parathyroid tissue typi-
cally results in normal parathyroid function [1]. In their nor-
mal state, parathyroid glands have no ducts (as do exocrine 
organs), follicles (as does the thyroid gland for thyroxine 
storage), or portal circulation (as do the hypothalamus and 
hypophysis). There is no need to reconstitute any type of 
structural arrangement to have parathyroid function from 
engineered or autografted cells. The cellular collections that 
develop from autografted parathyroid cells have the same 
bland appearance as normal parathyroid glands, without 
specifi c architectural arrangement, though the autografted 
tissue typically has less interposed adipose cells than a nor-
mal parathyroid gland.
Parathyroid cells are routinely autografted into hetero-
topic locations during the course of surgical therapy for thy-
roid or parathyroid diseases [17–19]. The only requirement is 
access to the microcirculation that develops spontaneously, 
and the glands can function in any site, though commonly 
placed in the musculature of the forearm or the presternal 
subcutaneous tissue. In preparation for tissue transplant, the 
parathyroid tissue is mechanically disrupted into small bits 
of tissue that can live from diffused nutrients at the trans-
plant site until neovascularization occurs. The parathyroid 
had protein expression of the parathyroid markers, we 
 performed immunofl uorescence (IF) for CXCR4, CaSR, 
and Sox17 (an earlier endoderm stage marker). We could 
not perform IF for GCM2 as no antibody is available either 
 commercially or privately. We also determined PTH expres-
sion by PTH ELISA. We found that CXCR4, CaSR, and Sox17 
were all expressed in the 12 day cells (Fig. 6B). However, the 
12 day cells had little to no PTH as determined by ELISA 
(Fig. 6C).
Since the cells differentiated by the Bingham  protocol 
did not express PTH, we cultured the 12 day cells in 12 





































FIG. 6. (Continued) (C) PTH ELISA. Conditioned medium 
was taken each step of differentiation from biological repli-
cates. The conditioned medium was tested in duplicate for 
the expression of PTH in a commercial PTH ELISA. Note that 
the 12-day cells did not express any PTH. Abbreviations: Act 
A, Activin A; d5, 5 days in differentiation culture (D’Amour 
protocol); d12, 12 days in D’Amour differentiation culture; 
Con, control cells (no differentiation); +1 wk or +2 wk, cells 
cultured for 1 or 2 week after day 12, no Activin A present. 
(D) Phase contrast images of cells that were in culture past 
12 days. Panel a: Cells that were in Activin A differentiation 
for 12 days (Bingham protocol) and kept for 1-week post-
removal of Activin A. Panel b: Cells that were in Activin A 
differentiation for 12 days (Bingham protocol) and kept for 
2-week post-removal of Activin A.
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 3.  Gordon J, VA Wilson, NF Blair, J Sheridan, A Farley, L Wilson, 
NR Manley and CC Blackburn. (2004). Functional evidence 
for a single endodermal origin for the thymic epithelium. Nat 
Immunol 5:546–553.
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patterning of pharyngeal pouch endoderm and pharyngeal 
endoderm-derived organs. Dev Biol 278:323–335.
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Eya transcriptional effects in mammalian organogenesis.[see 
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Nature 426:247–254.
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mouse embryonic stem cells: enrichment of endodermal cells in 
the embryoid body. Stem Cells 23:817–827.
10.  D’Amour KA, AD Agulnick, S Eliazer, OG Kelly, E Kroon and 
EE Baetge. (2005). Effi cient differentiation of human embryonic 
stem cells to defi nitive endoderm.[see comment]. Nat Biotechnol 
23:1534–1541.
11.  Kubo A, K Shinozaki, JM Shannon, V Kouskoff, M Kennedy, S 
Woo, HJ Fehling and G Keller. (2004). Development of defi nitive 
endoderm from embryonic stem cells in culture. Development 
131:1651–1662.
12.  Loebel DAF and PPL Tam. (2005). A gut feeling.[comment]. Nat 
Biotechnol 23:1491–1492.
13.  Micallef SJ, ME Janes, K Knezevic, RP Davis, AG Elefanty and 
EG Stanley. (2005). Retinoic acid induces Pdx1-positive endo-
derm in differentiating mouse embryonic stem cells. Diabetes 
54:301–305.
14.  Yasunaga M, S Tada, S Torikai-Nishikawa, Y Nakano, M Okada, 
LM Jakt, S Nishikawa, T Chiba, T Era and S-I Nishikawa. (2005). 
Induction and monitoring of defi nitive and visceral endoderm 
differentiation of mouse ES cells.[see comment]. Nat Biotechnol 
23:1542–1550.
15.  Doherty GM. (2006). Complications of thyroid and parathy-
roid surgery. In: Complications in Surgery. Mulholland MW, GM 
Doherty, eds. Lippincott, Williams & Wilkins, Philadelphia 
575–593.
16.  Carling T. (2001). Molecular pathology of parathyroid tumors. 
Trends Endocrinol Metab 12:53–58.
17.  Olson JA, Jr., MK DeBenedetti, DS Baumann and SA Wells, 
Jr. (1996). Parathyroid autotransplantation during thyroidec-
tomy. Results of long-term follow-up.[see comment]. Ann Surg 
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Sherwood. (1975). Transplantation of the parathyroid glands in 
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fragments are then placed into tissue and protected from 
direct trauma during wound healing. Resumption of mea-
surable, normal parathyroid function occurs in 6–10 weeks 
for patients who otherwise have no endogenous parathyroid 
function. The rate of complete normalization of parathyroid 
function after autograft of fresh parathyroid tissue is 70–95%. 
If the tissue is cryopreserved before autografting, the com-
plete function rate is 50–80% [1]. The autografted parathy-
roid tissue responds normally to changes in serum calcium 
concentration. Thus, the parathyroid gland is the optimal 
organ for replacement therapy. Attempts to utilize cellu-
lar replacement have been successful for hypoparathyroid 
patients either who have genetically identical parathyroid 
tissue available [20], or who are immunosuppressed to avoid 
rejection of a separate organ allograft (typically kidney) 
and thus tolerate a parathyroid allograft [19,21,22]. Allograft 
without immunosuppression has not been successful over 
the long term because of immune-mediated rejection [23]. 
Thus, the need exists for an optimal cellular replacement 
therapy not subject to immune rejection.
In the current studies, we have attempted to modify exist-
ing strategies for differentiating hES cells in vitro into defi n-
itive endoderm and, subsequently, into parathyroid glands. 
We have selected BG01 cells as a model system based upon 
their ability to express some markers of endoderm develop-
ment with undirected differentiation into EBs, suggesting 
that the cell line has not accumulated defects that may limit 
its ability to differentiate into endoderm. We used a differen-
tiation strategy described by D’Amour [10] to direct the cells 
toward an endoderm lineage. By adapting additional condi-
tions (Bingham protocol), we have defi ned an extended dif-
ferentiation strategy that induces the expression of markers 
of defi nitive parathyroid cells.
Signifi cant work remains to be done in order to settle 
on an optimal strategy for the development of parathyroid 
cells in vitro. Ongoing studies are evaluating the expres-
sion of the proteins in the cell culture; however, ultimately 
it will be important for the cells to have parathyroid func-
tion with calcium-responsive secretion of parathyroid 
hormone.
Ultimately, use of these differentiation techniques for 
patient care will require the identifi cation of an endogenous 
stem cell population that can be used as a starting point 
for differentiation and subsequent parathyroid autograft 
after in vitro differentiation. This could avoid the pitfall of 
immune rejection that limits the use of parathyroid allo-
graft currently. The optimal cell population for use is not yet 
determined; however, use of hESC provides an important 
and readily available model system to investigate the differ-
entiation strategy.
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